• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Itiation, shorter time to first treatment and overall survival. Additional fileAdditional file 1: Table S1. List of primers used in RQ-PCR studies. Table S2A. List of probes hypermethylated in CLL in comparison to CD19+ cells from healthy individuals. Table S2B. List of probes hypomethylated in CLL in Lenvatinib comparison to normal CD19+ cells. Table S3A. List of probes hypermethylated in unmutated in comparison to mutated CLL. Table S3B. List of probes hypomethylated in unmutated CLL in comparison to mutated CLL. Table S4. List of genes having negative correlation for methylation and gene expression in CLL as compared to normal 19+ cells. Table S5. List of genes having negative correlation for methylation and gene expression in unmutated CLL as compared to mutated CLL. (XLS 1339 kb)Acknowledgements We acknowledge Mr. Dhritiman Dan for the technical support.Rani et al. Clinical Epigenetics (2017) 9:Page 13 ofFunding The financial support was provided by the Department of Biotechnology (BT/PR11106/GBD/27/145/2008, BT/PR15438/MED/30/606/2011 and BT/ PR8680/AGR/36/754/2013), Ministry of Science and Technology, Government of India; and All India Institute of Medical Sciences, New Delhi (8-60/A060/ 2011/RS) to RG for carrying out this research work. Availability of data and materials The DNA methylation as well as expression data generated in the study have been submitted to the NCBI Gene Expression Omnibus (GEO) (http:// www.ncbi.nlm.nih.gov/geo/) under accession number GSE81937. Authors' contributions LR and NM performed all the experiments under the guidance of RG, analyzed the experimental data, and wrote the manuscript; RG designed the study, analyzed clinical and experimental data, and wrote the manuscript; GK contributed in validation experiments and reviewed the revised manuscript; AG, LK and AS evaluated the clinical data, and reviewed the manuscript; DS analyzed the experimental data and reviewed the manuscript; JKD helped DS in analysis of experimental data. All authors read and approved the final manuscript. Competing interests The authors declare that they have no competing interests. Consent for publication Not applicable. Ethics approval and consent to participate The study was approved by Institute Ethics Committee (AIIMS). All the patients were enrolled in the study after taking informed consent as per the guidelines of the institute ethics PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/3021955 committee. The study numbers provided by the committee were: A-03/25.07.2007, IEC/NP-129/2011, IEC/NP-25/2012 and IEC/NP-424/2013.7.8.9.10. 11.12.13.14.15.16.17.Publisher's NoteSpringer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.18.19. Author details 1 Laboratory Oncology Unit, Dr. B.R.A.IRCH, All India Institute of Medical Sciences (AIIMS), Ansari Nagar, New Delhi 110029, India. 2Department of Medical Oncology, Dr. B.R.A.IRCH, All India Institute of Medical Sciences (AIIMS), Ansari Nagar, New Delhi 110029, PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/18218841 India. 3Department of Biochemical Engineering and Biotechnology, DBT-AIST International Laboratory of Advanced Biomedicine (DAILAB), Indian Institute of Technology (IIT) Delhi, Hauz Khas, New Delhi 110016, India. Received: 28 June 2016 Accepted: 18 May20. 21.Wahlfors J, Hiltunen H, Heinonen K, H nen E, Alhonen L, J ne J. Genomic hypomethylation in human chronic lymphocytic leukemia. Blood. 1992;80:2074?0. Rush LJ, Raval A, Funchain P, Johnson AJ, Smith L, Lucas DM, et al. Epigenetic profiling in chronic lymphocytic leukemia reve.